Document is current
Any future updates will be listed below
-
Authors
Nel Van Zyl, K
Whitelaw, A. C.
Hesseling, A. C.
Seddon, J. A.
Demers, A-M
Newton-Foot, M.
-
Funding
Funding for this research was provided by:
Harry Crossley Foundation
UNITAID (Benefit-kids project)
Joint Global Health Trials Scheme of the Department for International Development, UK
Wellcome Trust
The Medical Research Council (MR/M007340/1)
South African Medical Research Council (SA MRC) Strategic Health Innovation Partnerships (S003805)
UK Medical Research Council (MRC) and the UK Department for International Development (MR/R007942/1)
National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (UM1AI06716)
NHLS Research Trust of South Africa (GRANT004_ 94632)
- License Information
-
More Information
Article History
Received: 7 March 2022
Accepted: 1 August 2022
First Online: 17 August 2022
Declarations
:
: The TB-CHAMP trial was approved by the South African Health Products Regulatory Authority (20160128), local health authorities and the Stellenbosch University Health Research Ethics Committee (SU-HREC, M16/02/009). This sub-study involved participants from the trial’s Cape Town sites only and ethical approval was obtained from the SU-HREC (S18/02/031). Written informed consent was obtained from the parents or legal guardians of the children. The research from both the parent trial and this sub-study were conducted as outlined by Stellenbosch University’s Policy for responsible research conduct in human participants and guidelines set out by the World Health Organization (WHO) and the Declaration of Helsinki.
: Not applicable.
: The authors declare that they have no competing interests.
